Key result
TAVI linked to new-onset atrial fibrillation in ~20% of patients within 30 days.
Why the study?
New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI).
What is the 30-day frequency of documented new-onset atrial fibrillation and its associated clinical and procedural factors in patients without prior atrial fibrillation undergoing transcatheter aortic valve implantation in Colombia?
Cohort (n=218)
No
What is the 30-day frequency of documented new-onset atrial fibrillation and its associated clinical and procedural factors in patients without prior atrial fibrillation undergoing transcatheter aortic valve implantation in Colombia?
Answers are grounded in this paper and cite their sources.
In a single-center Colombian TAVI cohort (2009–2023), approximately one in five patients (20.2%) had clinically documented new-onset atrial fibrillation within 30 days, with baseline COPD strongly associated with its occurrence.
Background New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI). Methods This retrospective cohort included 218 patients without documented pre-existing atrial fibrillation who underwent TAVI in Cali, Colombia, between 2009 and 2023. NOAF required an electrocardiographically documented episode lasting at least 30 s within 30 days. Clinical surveillance included inpatient telemetry and ECGs, scheduled follow-up and institutional readmissions; individual follow-up completeness was not quantified. We compared categorical characteristics and performed a sensitivity analysis restricted to recorded severe or critical aortic stenosis. Results NOAF was documented in 44/218 patients (20.2%; 95% CI, 15.4–26.0%). In the restricted subset, 35/164 had documented NOAF (21.3%; 95% CI, 15.8–28.2%). Chronic obstructive pulmonary disease was more frequent among patients with NOAF (61.4% versus 31.0%; unadjusted OR, 3.53; 95% CI, 1.78–7.01). Pacemaker implantation and low-molecular-weight heparin use were also more frequent in that group, describing perioperative co-occurrence. Conclusion Approximately one-fifth of patients had NOAF documented in the available records. Restriction to recorded severe or critical stenosis produced a similar frequency. The estimate describes clinical documentation within a 30-day window and requires interpretation in light of incomplete ascertainment and indication verification.
No takes yet. Share an insight, caveat, or question.
Montenegro-Palacios et al. (2026) conducted a cohort in Aortic valve disease undergoing transcatheter aortic valve implantation (TAVI) (n=218). Transcatheter aortic valve implantation (TAVI) was evaluated on Documented new-onset atrial fibrillation (NOAF) episode lasting at least 30 seconds within 30 days after TAVI (95% CI 15.4-26.0%). Transcatheter aortic valve implantation was associated with documented new-onset atrial fibrillation in 20.2% of patients within 30 days.
Synapse has enriched 10 related papers. Consider them for comparative context: